Clinical Trial Update: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

View source ↗

Summary

A completed observational study in France evaluates real-world outcomes of aflibercept in patients with wet age-related macular degeneration who were refractory…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• Lucentis (ranibizumab)

Snippet

Sponsor: Bayer | Conditions: Wet Macular Degeneration | Status: COMPLETED